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Summary
Objective: To review the current knowledge of the mechanism of DNA methylation, its association with transcriptional silencing, possible
mechanisms of hyper- and hypomethylation and how epigenetic changes may relate to the pathogenesis of osteoarthritis (OA).
Methods: Journal literature was searched using Pubmed. Since there are very few publications directly on epigenetic phenomena in OA, the
search was extended to give an overview of epigenetic mechanisms as they relate to the molecular mechanisms of the disease.
Results: While the epigenetics of cancer cells have been intensively investigated, little attention has so far been paid as to whether epigenetic
changes contribute to the pathology of non-neoplastic diseases such as OA. This review explains the mechanisms of DNA methylation, its role
in transcriptional regulation, and possible demethylation mechanisms that may be applicable to OA. Preliminary evidence suggests that
changes in DNA methylation, together with cytokines, growth factors and changes in matrix composition, are likely to be important in deter-
mining the complex gene expression patterns that are observed in osteoarthritic chondrocytes.
Conclusion: Early evidence points to a role of epigenetics in the pathogenesis of OA. Since epigenetic changes, although heritable at the cel-
lular level, are potentially reversible, epigenetics could be a new molecular target for therapeutic intervention, especially early in the disease.
ª 2006 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Osteoarthritis (OA) represents a disease group with differ-
ent underlying pathophysiological mechanisms, however,
one common key event is the destruction of the extracellu-
lar matrix of articular cartilage by aggrecanases and colla-
genases. There are two possible sources for these
enzymes: the synovium and the articular chondrocytes. It
has been shown that degradative enzymes are present in
the inﬂamed synovium. Inﬂammatory episodes could be im-
portant for the initiation of the disease or a low level of in-
ﬂammation could contribute to progression of the disease.
During OA, an increasing number of articular chondrocytes
undergo a phenotypic modulation1 either to cells with hyper-
trophic characteristics2,3 or to cells that may be regarded as
‘degradative’ chondrocytes4. These latter cells can synthe-
size all the known cartilage-degrading proteases and thus
probably play a decisive role in the progression of the dis-
ease. The phenotype of normal chondrocytes, as that of
all adult somatic cells, is stabilized by the epigenetic status
of the cell. This raises the question as to whether the desta-
bilization of the chondrocytic phenotype in OA is at least in
part the result of changes in this epigenetic status. While
SAM S-adenosyl-methionine
Sp1 speciﬁc protein 1
Tat tyrosine aminotransferase
TNF tumor necrosis factor
kB kappaB
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gated extensively5e7, few studies have addressed the
question whether epigenetic changes contribute to the path-
ogenesis of other diseases such as OA. This review pres-
ents and discusses what is known about pathological
changes in epigenetic status and whether this might be of
relevance for OA.
Methods
We used Pubmed (www.ncbi.nlm.nih.gov/entrez) as the
search engine. Initially, we searched for ‘‘DNA methyla-
tionþ chondrocytes’’ and ‘‘DNA methylationþOA’’. This
was followed by searches for review papers regarding the
mechanism of DNA methylation, using the search combina-
tions ‘‘epigeneticsþ review’’ and ‘‘DNA methylationþ re-
view’’. No speciﬁc date limits were applied, but more
recently published papers were selected to a greater extent.
Many references cited in the primary papers were also read.
Some topics, which are of particular relevance for OA were
followed in greater depth, e.g., ‘‘NF-kBþmethylation’’ and
‘‘IL-1bþmethylation’’. From all available papers a selection
was made, judged according to relevance and importance.
Results
WHAT IS EPIGENETICS?
Epigenetics (literally ‘‘beyond genetics’’) is deﬁned as
heritable changes in DNA without changes in the sequence.
While the genetic code is identical for every somatic cell in
the body, epigenetic changes are generally conﬁned to spe-
ciﬁc cells/tissues or even cells within a tissue. Epigenetic
control mechanisms involve modiﬁcations of chromatin.
Broadly speaking, there are two major epigenetic modiﬁca-
tions: (1) DNA methylation and (2) histone modiﬁcations,
such as acetylation, methylation and phosphorylation.
Both are parts of the same epigenetic program and usually
work hand-in-hand in gene-silencing8,9. On the whole, con-
formationally relaxed chromatin (euchromatin) indicates
transcriptionally active regions and is associated with hypo-
methylated DNA and acetylated histones, whereas compact
chromatin (heterochromatin) is transcriptionally silent, hy-
permethylated and bound to non-acetylated histones. Since
histone acetylation and chromatin condensations are fre-
quently a consequence of DNA methylation, the latter is
probably the principal mechanism by which cells maintains
a stable chromatin conﬁguration that represses transcrip-
tion. Methylation patterns are normally stable, and inherited
upon mitosis in adult cells. Deviations are associated with
diseases (recently reviewed in Refs. 10e13).
DNA methylation occurs through the addition of a methyl
group to cytosine (C) to form methylated cytosine (MeC).
This happens particularly to those cytosines that are 50 to
guanines (G), the so-called CpG sites, where ‘p’ represents
the phosphate connecting the two nucleotides. This is me-
diated by enzymes known as DNA methyltransferases
(Dnmts), which catalyze the transfer of a methyl group
from S-adenosyl-methionine (SAM) to the cytosine base
to form MeC (see Fig. 1). Methyl donors are folic acid and
choline, which are dietary requirements, as are the co-fac-
tors vitamins B6 and B12 and zinc. Several methyltrans-
ferases have been identiﬁed: Dnmt1, Dnmt3a and Dnmt3b
and the splice variants Dmnt1a and Dmnt1b (reviewed by
Pradhan and Esteve14). Dnmt1 is responsible for maintain-
ing established methylation patterns during cell division.Expression is induced at the entrance into the S-phase15,
its abundance is reduced to low levels at the G0-phase
and the enzyme is not detectable in growth-arrested cells.
During mitosis, Dmnt1 is targeted to replication foci through
its interaction with the DNA polymerase clamp proliferating
cell nuclear antigen (PCNA)16,17, detects hemi-methylated
CpGs in the parent DNA strand and replicates the methyla-
tion pattern on the newly-formed strand. Dnmt3a and
Dnmt3b are known to play key roles in the de novo methyl-
ation of primarily unmethylated DNA and are important in
establishing the methylation pattern during development14.
In early fetal development, tissue differentiation is to a
large extent determined through mechanisms involving
methylation changes of the genomic DNA, resulting in
phenotype-speciﬁc activation of expressed genes together
with silencing of non-expressed genes.
About 70% of CpG sites within the mammalian genome
are methylated6. It is thought that methylation evolved ini-
tially as a protective mechanism in limiting expression of for-
eign DNA, such as transposons, intragenomic parasites
and proviral DNA, which threatens the orderly expression
of the genome. Around 40% of human DNA consists of
such ‘junk’ DNA, thus silencing this potentially harmful
DNA by methylation is of obvious importance for host de-
fense. However, DNA methylation is also essential for nor-
mal cellular functions, in particular imprinting of speciﬁc
genes, X chromosome inactivation in the female and,
most importantly in the present context, cell-type speciﬁc
gene expression through permanent silencing of all genes
that are not expressed in a particular somatic cell.
THE ROLE OF EPIGENETICS IN TRANSCRIPTIONAL
REGULATION
Gene expression is controlled by multiple mechanisms:
(1) at a genetic level, the DNA sequence of the promoter
and other regulatory regions is important, in particular which
binding sites for regulatory proteins are present; (2) at the
molecular level, the availability of nuclear regulatory factors,
such as transcription factors, enhancers and suppressors
will inﬂuence gene transcription; and (3) at an epigenetic
level, it will be determined whether or not the gene is perma-
nently silenced in the particular somatic cell so that neither
(1) nor (2) can play a role. For example, the silencing of in-
terferon regulatory factor 4 in leukemic cells was due to hy-
permethylation of CpG sites in the promoter18. The opposite
situation occurs during muscle differentiation, where loss of
methylation at one speciﬁc CCGG site in the promoter
region of myogenin was correlated with transcriptional
Fig. 1. The chemistry of DNA methylation. SAM is the methyl donor
and becomes converted to S-adenosyl homocysteine through the
action of DNA methyltransferases.
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ride the activities of transcription factors is illustrated by the
regulation of the Apaf-1 gene, which plays a central role in
DNA damage-induced apoptosis20. Some leukemia cell
lines express the factor, while others do not. The expres-
sion of factors regulating Apaf-1 expression, such as E2F-
1, p53 and speciﬁc protein 1 (Sp1), did not differ between
Apaf-1 positive and Apaf-1 negative cells, and the inactiva-
tion could be attributed to silencing by methylation20. Other
examples of genes, whose tissue-speciﬁc expression has
been shown to be controlled by DNA methylation, can be
found in the review by Ehrlich21.
How does methylation silence gene transcription? There
are three possibilities (see Fig. 2): (1) access of transcrip-
tion factors may be prevented directly by the presence of
methyl-groups; (2) the latter attract methyl-binding proteins
and histone deacetylases, which itself may prevent tran-
scription factor binding and/or (3) cause remodelling to tran-
scriptionally inactive heterochromatin (reviewed in Refs.
10,22e24).
Several methyl-CpG binding domains (MBD) have been
identiﬁed (reviewed in Refs. 25,26), some of which form
part of methyl-CpG-binding protein (MeCP) complexes. Of
particular importance with regard to transcriptional repres-
sion are MeCP1 and MeCP227. Both contain transcriptional
repression domains and are associated with histone deace-
tylase28,29. MeCP1 contains MBD2, while MeCP2 contains
the transcriptional suppressor mSin3A29. These methyl-
binding proteins are preferentially recruited to methylated
DNA and their associated histone deacetylase activity
leads, under normal circumstances, to hypoacetylated his-
tones30. Methyl-binding proteins thus link these two epige-
netic processes. Trichostatin A, a speciﬁc inhibitor of
histone deacetylase, can reverse the process, which may
lead to upregulation of non-methylated or sparely methyl-
ated promoters, but not hypermethylated genes, indicating
that CpG island methylation is dominant for a silent state30.
On the other hand, some studies suggest that histone mod-
iﬁcations are a pre-requisite for DNA methylation, suggest-
ing that histone modiﬁcations are the primary events in
gene silencing31,32,8.
Whatever the sequence of events in gene silencing, the
methylation status in the promoter regions determineswhether the gene is silenced or can be transcribed if the ap-
propriate regulatory factors are present. Promoters vary
considerably with regard to the number of available CpG
sites. At one extreme are those that contain only a few
CpG sites. These are the so-called ‘sparse CpG’ promoters
(Fig. 3 left-hand side). For example, only seven CpG sites
are found in the 2000 bp 50 ﬂanking region of matrix metal-
loproteinase (MMP)-3. Similarly, the degradative proteases
MMP-9, -13 and the aggrecanase ADAMTS-4 (a disintegrin
and metalloproteinase with thrombospondin motifs) have
sparse CpG promoters33. At the other extreme, some pro-
moters have a high concentration of CpGs, the so-called
‘‘CpG island’’ promoters (Fig. 3 right-hand side). For exam-
ple, in the collagen type II a1 gene there are 65 CpGs in the
850 bp region upstream of the start of exon1. All house-
keeping and tumor suppressor genes have CpG islands in
their promoters and these islands contain multiple binding
sites for transcription factors34, especially for Sp135,36. Bind-
ing of Sp1 keeps the islands methylation-free, which makes
intuitive sense, since these genes must be expressed in all
cells. About half of the mammalian genes have CpG islands
within or near their promotor regions 37. The remaining
CpG-elements are found more or less randomly distributed
throughout the genome.
The efﬁciency of repression by DNA methylation may de-
pend on (1) methylation of a single crucial CpG site38; (2)
the total number of methylated CpGs; or (3) the presence
of an enhancer element39,40, see Fig. 3. It is of note that
the two methyl-CpG-binding proteins MeCP1 and MeCP2
differ in their preference for CpG sites. MeCP1 requires
multiple, closely spaced CpGs and thus binds preferentially
to CpG island promoters, but MeCP2 binds preferentially to
single CpG sites, where it covers approximately 12 bp of
DNA41,27. If the promoter is a weak promoter with no en-
hancer element, then methylation will repress transcription
in both sparse and island promoters [Fig. 3(B)]. However,
if the promoter contains a strong enhancer element
[Fig. 3(C)], transcription may not be repressed in a gene
with a sparse CpG promoter, possibly because the en-
hancer element prevents binding of the methyl-binding pro-
teins. However, transcription will continue to be repressed
in a gene with an island promoter even in the presence of
an enhancer element. It should be noted that not all CpGsFig. 2. Mechanisms of silencing. (A) Binding of transcription factors is prevented directly by the presence of methyl groups on CpG sites.
(B) Methyl-binding domains have attached to the methylated cytosines and this prevents binding of transcription factors. A third mechanism
is the tight packaging of methylated DNA, which is generally associated with methylated DNA and deacetylated histones (not shown).
(C) Demethylation would be required for active transcription of the gene.
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ther do all CpGs require methylation for repression of tran-
scription. Binding of methyl-binding proteins will promote
chromatin condensation into an inactive conformation so
that gene expression can be affected at a distance from
the methylated region25.
Examination of methylation status in promoters with
sparse CpGs has been neglected, largely because it was
thought that methylation of many CpGs was needed to re-
press gene transcription. This may be true for promoters
with enhancer elements, but, as Fig. 3(B) illustrates, silenc-
ing of genes by DNA methylation is feasible in genes with
sparse CpG promoters. It is possible that the likelihood of
pathological demethylation is greater in sparse island
promoters.
DEMETHYLATION MECHANISMS
In essence, demethylation of the DNA can occur through
passive or active mechanisms. Active mechanisms would
involve a direct removal of the methylated moieties, while
passive mechanism would involve inhibition of the mainte-
nance methylation during cell division42. Both active and
passive mechanisms are thought to occur during the epige-
netic reprogramming that occurs in the zygote after fertiliza-
tion43. The paternal genome is rapidly demethylated in the
fertilized oocyte without cell division, hence must involve ac-
tive demethylation44, whereas methylation of the maternal
genome is lost more gradually between the one-cell and
eight-cell stage, suggesting passive demethylation45,43.
Passive demethylation: This results if Dnmt1 is not able
to catalyze the methylation of the daughter DNA strand.
The may be due to the presence of DNA binding proteins
or factors inhibiting the enzyme directly. It is theoretically
Fig. 3. The effects of methylation on transcription in two types of
promoters. Non-methylated CpG sites are shown as vertical lines
with red circles illustrating methylated CpGs. A sparse CpG pro-
moter is illustrated on the left, an island promoter on the right. (A)
If the majority of CpGs is not methylated in either promoter, tran-
scription factors (blue ovals) can bind and initiate transcription.
Note that an occasional methylated CpG may not be sufﬁcient to
prevent transcription. (B) Here most CpGs are methylated, which
attract methyl-binding proteins. MeCP2 (yellow) is capable of bind-
ing to individual CpGs, while MeCP1 (green) requires several
closely spaced CpGs. This prevents transcription factors binding
and thus transcription in either promoter. (C) If the promoter con-
tains a strong enhancer element, upstream or downstream from
the promoter region (not shown in this diagram), then this may over-
come the silencing effects of CpG methylation in sparse CpG pro-
moters, but not in island promoters. The enhancer may act by
preventing the binding of methyl-binding proteins (as shown in
the diagram).feasible for speciﬁc transcription factors to bind to the
DNA and prevent methylation of the newly-synthesized
strand at a speciﬁc and limited site only, see Fig. 4(A). On
the other hand, there maybe an overall inhibition of the en-
zyme, resulting in complete non-methylation of new strand,
see Fig. 4(B).
This mechanism does not require any demethylases, but
is comparatively inefﬁcient, as it is dependent on several
replication cycles: three rounds of replication demethylate
only 87% of CpGs46. Such mechanism would thus not be
suitable for rapid reprogramming of gene expression. The
experimental demethylation agent 5-aza-cytidine or 5-aza-
20-deoxycytidine mimics passive demethylation by the
second mechanism.
Active demethylation: Theoretically, there are three possi-
ble biochemical mechanisms: (1) a direct replacement of
the methyl group with hydrogen; (2) excision of the methyl-
ated base while keeping the phosphodiester backbone in-
tact; or (3) excision of the methylated cytosine46, possibly
together with adjacent nucleotides (see Fig. 5).
However, enzymes with relevant activities have been
rather elusive. Although the methyl-binding domain MBD2
was credited with a demethylase activity that cleaved the
methyl residue47,48, this was not conﬁrmed by other
Fig. 4. (A) Following DNA replication, the methylation status is nor-
mally faithfully reproduced by the maintenance Dnmt1, which asso-
ciates with the DNA clamp PCNA. (B) Speciﬁc DNA binding factors
may prevent the methylation of speciﬁc CpG sites by temporarily in-
hibiting Dnmt1 through steric hindrance or (C) the enzyme itself
may be completely inhibited so that no cytosines are methylated
on the new DNA strand (reproduced with permission from Ref. 46).
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breaks and if the nucleotides on both strands were excised
simultaneously, the total structure would be disrupted. So
the second mechanism appears the most feasible. Indeed,
there is evidence for a mechanism that resembles ‘‘base
excision DNA repair’’ activity. In chick embryos, a MeC-
DNA glycosylase has been identiﬁed, which acts preferen-
tially on hemi-methylated DNA (which could have resulted
from passive demethylation) and initiates demethylation
by breaking the glycosidic bone of MeC49. Interestingly,
the MeC-DNA glycosylase co-puriﬁes with the guanine/thy-
midine (G/T) mismatch DNA glycosylase50. In humans,
MeC-DNA glycosylase as well as the G/T mismatch glycosy-
lase activity is associated with the MBD4 complex51 as well
as PCNA52, binding selectively to hemi-methylated DNA,
and initiating demethylation of the still methylated strand.
Probably the most efﬁcient way to achieve demethylation
of both strands is a passiveeactive mechanism, where
inhibition of Dnmt1 is followed by activity of the MeC-DNA
Fig. 5. Possible levels of action of demethylases: (1) methyl exci-
sion; (2) excision of the methylated base; and (3) excision of the nu-
cleotide, maybe together with adjacent nucleotides, i.e., the whole
CpG element (reproduced with permission from Ref. 46).glycosylase and associated factors. This would achieve de-
methylation in one round of cell division and avoid double-
stranded DNA breaks. The fact that MeC-DNA glycosylase
catalyzes demethylation preferentially on hemi-methylated
DNA strands supports this notion.
IS EPIGENETICS INVOLVED IN THE DEVELOPMENT
AND PROGRESSION OF OA?
Alterations in epigenetic state are likely to have occurred
in situations where there is a fundamental change in the
gene expression repertoire (not just a single gene) and
this changed expression is transmitted to daughter cells.
In normal articular chondrocytes, most proteases are not
expressed, hence these genes would be expected to be si-
lenced by DNA methylation. However, osteoarthritic chon-
drocytes neo-express many genes involved in cartilage
catabolism, for example matrix-degrading enzymes such
as MMP-253, MMP-954e57, MMP-1358e60 and ADAMTS-4
and -560,61. These enzymes are expressed predominantly
by chondrocytes in the superﬁcial region that have started
to proliferate and formed clones62,4.
Expression might start in a few isolated cells near the sur-
face; these cells might divide to produce doublets, quadru-
plets, etc. and, ﬁnally clusters of many cells. This is
illustrated in Fig. 6. OA cartilage is graded in histological
sections, using either the Mankin score (ranging from 0 to
14) or the more recently developed Osteoarthritis Research
Society International (OARSI) grade (ranging from 0 to 6)63.
When the Mankin score/OARSI grade is low, MMP-positive
chondrocytes are present as single cells or as one cell of
a cell doublet near the surface [Fig. 6(A)]. This ﬁgure shows
that with increasing OA grade, cells divide to become dou-
blets (B) and quadruplets (C) until, in high-grade OA, all
cells are in the form of immunopositive clones [(D), shown
for MMP-9, but also found for MMP-3, -13 and ADAMTS-
44]. One possible explanation for this is that whatever fun-
damental change had occurred in individual chondrocytes
to cause the expression of aberrant genes, this change
was transmitted to the daughter cells during cell division,
i.e., the change was heritable at a cellular level, consistent
with an epigenetic change. The challenge is obviously to in-
vestigate whether the de novo expression of aberrant gene
was indeed accompanied by loss of DNA methylation in the
relevant promoter region.Fig. 6. Increase in the number of MMP-9 positive chondrocytes with increasing Mankin score. (A) At MS¼ 1, only a few single cells are im-
munopositive. (B) The positive cells are present in doublets at MS¼ 4. (C) Quadruplets are seen at MS¼ 7, while (D) in severe OA (MS> 10),
all cells of the typical clones are immunopositive for MMP-9 (reprinted with permission from Ref. 4).
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DEVELOPMENT AND PROGRESSION OF OA?
Aging is the most prominent risk factor for OA, but the ex-
planations for this strong association remain largely unclear
with some concepts for cellular changes emerging more re-
cently (for review see Aigner et al.64). We would like to pro-
pose that changes in DNA methylation are not only part of
these age-related changes within the cells but may also fol-
low exposure to inﬂammatory cytokines, such as interleu-
kin-1 (IL-1) b and tumor necrosis factor (TNF) a. These
cytokines down-regulate the expression of chondrocytic
genes, but induce expression of several matrix-degrading
proteases when added to monolayer cultures of human or
bovine articular chondrocytes (for reviews, see Refs.
65e68). Experimental data suggest that IL-1b is also pro-
duced in vivo by those OA chondrocytes that are positive
for proteases69. Could cytokine induced changes in gene
expression pattern include changes in DNA methylation sta-
tus? This has not yet been investigated in OA, but, as out-
lined below, there is indeed some preliminary evidence for
a link between cytokine activity and both hypermethylation
of CpG islands as well as loss of methylation.
An example of IL-1b-induced methylation-dependent
gene silencing in a CpG island promoter is the fragile X
mental retardation one gene that is located in the active X
chromosome70. In fragile X syndrome, this gene is abnor-
mally hypermethylated, which leads to repression and char-
acterizes (together with expansion of CGG repeats) the
syndrome. IL-1b repressed the gene by hypermethylation
of the CpG island, an effect that was mediated via nitric
oxide (NO), since NO donors also caused gene silencing,
whereas inducible NO synthase inhibitors prevented the
IL-1b mediated repression and hypermethylation. Both NO
and IL-1b seemed to act by increasing the activity, but not
gene expression, of a DNA methyltransferase, presumably
one of the de novo methyltransferases Dnmt3a or Dnmt3b.
Interestingly, those chondrocytic genes that might be
repressed by IL-1b and/or TNFa during OA, for example,collagen II and aggrecan, also contain CpG islands in their
promoters and NO is also induced in OA71,72. However,
there is no evidence to date that repression of chondrocytic
genes involves hypermethylation of the CpG islands.
Poschl et al.73 investigated whether the loss of aggrecan
expression in OA was linked to increased methylation of
the promoter and could not demonstrate hypermethylation
as a possible cause for silencing of this chondrocytic
gene. However, only a relatively short region of the pro-
moter was examined and the possibility that changes in
DNA methylation at non-examined CpG sites have taken
place cannot, as yet, be excluded.
Data on DNA demethylation in relation to arthritis are also
sparse. Kim et al.74 found that inﬂammatory arthritis was as-
sociated with overall DNA hypomethylation in peripheral
blood mononuclear cells, but did not investigate speciﬁc
genes or chondrocytes. The ﬁrst speciﬁc gene examined
was MMP-9, whose expression is increased in OA54. The
670 bp promoter sequence75 contains just six CpG sites.
Using the methylation-sensitive restriction enzyme method,
Roach et al. were able to demonstrate a difference in meth-
ylation status of AciI digestible sites: three CpG sites in the
proximal promoter and two CpG sites in the distal promoter
of MMP-9 were methylated in 4/5 control patients, but that
at least one of these sites was unmethylated in 8/9 OA pa-
tients33. Further studies investigated the methylation status
of the promoters of MMP-3, -13 and ADAM-TS4 in addition
to MMP-9. Notably, all these promoters contain relatively
few CpGs, which, as already mentioned, might favor patho-
logical demethylation. The methylation status of these
CpGs was examined in DNA extracted from the superﬁcial
zone of OA cartilage (which contained the protease-ex-
pressing chondrocytes) and, for controls, the deep zone
from fracture-neck-of-femur (#NOF) patients (Fig. 7: pres-
ence of methylation is indicated by presence of bands
and vice versa). The expectation had been that all CpG
sites would be methylated in control samples and unmethy-
lated in OA samples. This was not the case. Speciﬁc CpG5’ flanking region of MMP-13 5’ flanking region of MMP-9
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Fig. 7. Representative results of PCR ampliﬁcations of the promoter regions with or without digestion by methylation-sensitive restriction
enzymes. A typical pattern of reactions is shown for DNA extracted from the deep zone of a patient with femoral neck fracture (#NOF)
and from the surface zone around the weight-bearing area of an OA patient. The ladder shows 200 bp intervals and the location of CpG sites
is indicated by the numbers (reprinted with permission from Ref. 4).
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from sites with ubiquitous methylation in all patients (Fig. 7:
arrow heads) to sites with no methylation in both control and
OA samples (Fig. 7: *). However, there were CpG sites,
where loss of methylation had occurred in most OA pa-
tients, whereas methylation was present in most #NOF pa-
tients (Fig. 7: arrows). It is feasible, though not yet proven,
that these speciﬁc CpG sites are crucial for the epigenetic
regulation of gene transcription, possibly along with the
overall levels of methylated CpGs, since the overall per-
centage of non-methylated CpGs increased from 20% in
controls to 48% in the degradative chondrocytes of OA pa-
tients. However, there was considerable variation between
patients and, although these studies have shown an asso-
ciation between methylation status and gene expression,
it has not yet been proven that loss of methylation is the
cause of transcriptional activation for these degradative
enzymes.
POSSIBLE DEMETHYLATION MECHANISMS IN OA
If demethylation of speciﬁc CpG sites was responsible for
permitting aberrant gene transcription, by what mechanisms
could this occur? One possibility is a random loss of meth-
ylation simply due to aging6,34,76 or cellular senescence77,78
via passive demethylation. However, the overall methyla-
tion content in OA cartilage does not change (unpublished
data) and there does not appear to be random loss of meth-
ylation in all genes. So could demethylation mechanisms be
targeted to speciﬁc genes? So far no studies have been
carried out to determine this in chondrocytes or OA. There
are, however, several studies is other systems, whose re-
sults are of importance inasmuch as they illustrate possible
mechanisms that might also be applicable to OA.
It was stated earlier that methylation generally prevents
binding of transcription factors and other DNA binding pro-
teins. However, not all binding is inhibited by DNA methyla-
tion and binding of certain DNA binding proteins can
actually initiate demethylation. Hsieh79 used plasmids
containing the latent replication origin (oriP) of the Epsteine
Barr virus (EBV), transfected into human cells expressing
the EBV nuclear binding factor EBNA-1. In this system an
artiﬁcial CpG methylation pattern was generated in the plas-
mids in vitro by using the FnuII, HhaI, HpaII and SssI meth-
ylases, which methylate the CpGs located near their
respective recognition sequences or, in the case of SssI,
at all CpG sites. This pattern was maintained for months af-
ter transfection into human cells, conﬁrming that the mainte-
nance methyltransferase could maintain the artiﬁcially
created CpG pattern during cell divisions. However, three
HpaII sites (CCGG) in the oriP region always became de-
methylated very quickly after transfection into the human
cells expressing EBNA-1, but one HpaII site did not. No
EBNA-1 binding sites were present near this latter HpaII,
whereas the other three were close to several EBNA-1
binding motifs. Neither replication alone nor binding of
EBNA-1 alone led to demethylation, but binding of EBNA-
1 followed by replication led to demethylation of the CpGs
at the three CCGG sites, but not at CpG sites adjacent to
or in between the CCGG locations. Hemi-methylated DNA
was detected after one round of replication, but demethyla-
tion of the second strand probably occurred without further
replication, implicating a passiveeactive mechanism79. This
study thus provided clear evidence that speciﬁc DNA bind-
ing proteins can protect speciﬁc CpGs from the activities of
the maintenance Dnmt1, resulting in passive methylationof the ﬁrst strand, possibly followed by active demethylation
of the second strand.
The previous example depended on artiﬁcially methyl-
ated constructs. An example where DNA binding proteins
achieved demethylation of speciﬁc CpGs in a tissue-spe-
ciﬁc gene in its natural chromatin context is the demethyla-
tion within an enhancer element of the rat liver-speciﬁc
tyrosine aminotransferase (Tat) gene during develop-
ment80. This gene is induced at birth by glucocorticoid in re-
sponse to hypoglycemia, but is not inducible before birth.
Induction is facilitated by two glucocorticoid responsive
units (GRU) located at 2.5 bp and 5.5 bp. These GRUs
contain numerous and overlapping sites for glucocorticoid
receptor (GR) and transcription factors, such as C/EBP,
HNF-3 and ets families. The 2.5 bp GRU also contains
three closely spaced CpG sites, plus a fourth at 2341. Be-
fore birth, when the Tat gene is not inducible, these CpG
sites are methylated, but non-methylated after birth.
Thomassin et al.80 treated rat hepatoma cells with dexa-
methasone. Short-term (<1 h) treatment caused reversible
chromatin remodelling and HNF-3 binding, whereas pro-
longed treatment over 3 days resulted in progressive deme-
thylation at all three sites as well as the fourth more distal
CpG site, which was still within the 350 bp area of chromatin
remodelling. These CpG sites were not re-methylated during
subsequent 3 months culture without dex, as would be ex-
pected if a change in methylation status had occurred. If
na€ıve methylated cells or demethylated cells were treated
with glucocorticoid, transcription induction was faster and
stronger in the demethylated cells. Moreover, binding of
two further transcription factors was only possible in the de-
methylated cells. The authors propose that initial glucocorti-
coid and HNF-3 binding just prior to birth induce loss of
methylation that primes the GRU to subsequent induction
in response to hypoglycemia after birth.
These ground-breaking studies suggest that one mecha-
nism for demethylation at deﬁned CpG sites in speciﬁc
genes involves speciﬁc DNA binding proteins/transcription
factors that initially prevent Dnmt1 from methylating the cy-
tosine on the newly-synthesized strand during one round of
cell division, followed by active demethylation of the second
strand. Could such a mechanism be involved in the deme-
thylation of speciﬁc CpGs in the promoters of the aberrantly
expressed degradative enzymes? At present, we do not yet
know the answer, but the results from a study of B-cell mat-
uration by Kirillov et al.81 are of relevance. The immuno-
globulin k gene is demethylated at speciﬁc CpG sites
during B-cell maturation, a process driven by several cis-
acting regulatory elements, to which speciﬁc trans-
acting factors bind in a stage and tissue-speciﬁc manner.
Using mutation and complementation analysis, these au-
thors showed that demethylation was dependent on a kap-
paB (kB) binding site and presence of the rel/NF-kB family
of transcription factors. Cell lines with defective nuclear
kB-binding proteins were unable to carry out demethylation,
but this was restored by introducing relB.
Many of the degradative proteases that are induced in
OA have NF-kB binding sites in their promoters. Moreover,
NF-kB is activated by cytokines such as IL-1b82e85 and
TNFa. Hence NF-kB could be one of the DNA binding fac-
tors that initiates DNA demethylation, but other factors,
such as members of the ets family, could also be involved.
Clearly further research is required to determine the inter-
relations between the signal transduction of IL-1b and
TNFa (and perhaps other inﬂammatory cytokines) and
DNA methylation status of speciﬁc genes in chondrocytes
during OA.
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Methylation of genomic DNA clearly represents a very im-
portant mechanism in order to determine tissue and cell dif-
ferentiation. DNA methylation is not so much a tool for the
regulation of single genes, rather it is involved in the setup
of a cellular phenotype, implicating as such ﬁxed expres-
sion levels of many genes. DNA methylation is heritable
and transmitted to daughter cells. This means that, under
normal circumstances, a particular phenotype is stably
propagated. However, when aberrant changes in methyla-
tion do occur, then these changes are also propagated to
daughter cells, since a particular cell type has no way of ‘‘re-
membering’’ what its appropriate methylation status ought
to be. Aberrant methylation patterns are involved in impor-
tant pathologies such as tumorigenesis and complex
non-Mendelian diseases, such as Alzheimer’s, lupus eryth-
ematosus or psychiatric disorders. First experimental evi-
dence suggests that changes in methylation patterns
could also underlie the changed gene expression patterns
observed in OA. To what extent this is the case and whether
this can be inﬂuenced in terms of therapy should be a major
interest for further research.
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